Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMARANTH: Lanabecestat in Early Alzheimer's Disease
NCT02245737Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale (13-item) at Week 104. Started Sep 2014; status: terminated.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02245737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245737.